![[UPDATE] University of Bridgeport and Goodwin University Revolutionize Regenerative Medicine Training Program Forming Strategic Alliance with Globally Recognized TulsiHub Institute](/_next/image?url=https%3A%2F%2Fimages.businessupturn.com%2Fwp-content%2Fuploads%2F2023%2F08%2Fupturn-logo_final_Artboard-1-copy-9-1024x576.jpg&w=3840&q=100){kind=logo}
[UPDATE] University of Bridgeport and Goodwin University Revolutionize Regenerative Medicine Training Program Forming Strategic Alliance with Globally Recognized TulsiHub Institute
BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) — The two leading academic institutions have joined forces with TulsiHub Institute, the premier provider of advanced CE certified regenerative medicine certification programs, to transform medical education standards across regenerative medicine and cellular therapy disciplines. This innovative alliance positions both universities as pioneers in cutting-edge healthcare training while establishing new industry standards for professional medical certifications and continuing medical education in the rapidly expanding regenerative healthcare sector.
Universities Pioneer Advanced Regenerative Medicine Education Partnership
With the global regenerative medicine market expected to expand from $60 billion in 2023 to over $375 billion by 2031, this exponential growth creates significant demand for qualified practitioners capable of delivering advanced regenerative treatments including stem cell therapy, tissue engineering, and cellular therapy applications.
The collaboration establishes both institutions as pioneers in advanced healthcare education, directly responding to the urgent need for comprehensive regenerative medicine training in the United States. This partnership addresses critical gaps in medical education across multiple regenerative medicine disciplines, including stem cell therapy, gene therapy, tissue engineering, cellular therapy, PRP (Platelet Rich Plasma) therapy, EBOO Therapy, Exosome therapy, Prolotherapy, and Shockwave therapy.
'It's a call to shape the very future of medicine,' remarked President Mark E. Scheinberg. 'We are excited to help forge a new generation of healthcare professionals who will redefine what's possible in patient care.'
First-of-Its-Kind CE Certified Regenerative Medicine Training Program in the U.S.
Through this strategic alliance, students gain access to the first intensive and comprehensive CE certified regenerative medicine training program of this caliber in the United States. The program features 12 specialized medical courses delivered through a unique 8-to-12-week intensive training methodology that combines theoretical medical knowledge with extensive practical training, ensuring certified healthcare professionals achieve clinical competency in cutting-edge regenerative medicine techniques.
The evidence-based curriculum provides healthcare professionals with comprehensive on-site instruction under expert medical supervision with extensive hands-on experience. This approach ensures graduates possess both theoretical understanding and practical expertise in regenerative medicine applications, responding to urgent market demand from healthcare professionals seeking advanced training in regenerative therapies without geographic barriers.
Students benefit from generous scholarships provided by TulsiHub Institute, along with access to seed funding opportunities of US$100,000 for establishing their own regenerative medicine clinics, and favorable lifetime discounts on medical consumables to support the ongoing success of their practices. This comprehensive support system addresses the practical implementation challenges newly certified practitioners face, providing essential financial resources to successfully transition from training to clinical application.
'This strategic collaboration establishes our institution as a leader in advanced healthcare education while reinforcing our dedication to equipping students and medical professionals with innovative training programs that address evolving industry requirements,' said University of Bridgeport President Danielle Wilken, Ed.D.
Global Leader in Regenerative Medicine Certification
TulsiHub Institute consortium maintains an exceptional 98% certification success rate while delivering internationally recognized credentials to medical professionals across 25 countries worldwide. As the gold standard in CE certified regenerative medicine certification, they have successfully certified over 500 healthcare professionals through comprehensive training programs.
'This partnership marks the first and only intensive and comprehensive CE certified regenerative medicine training program of this caliber available in the United States. We are responding to urgent market demand from healthcare professionals seeking advanced training in regenerative therapies without geographic barriers,' said Dr. Natasha Macleay, CEO of TulsiHub Institute.
This institution also offers comprehensive certification programs equipping students with the latest advancements in longevity, preventive care, anti-aging protocols, in specialized areas like Dermatology, Orthopedics, Oncology Care, and Dentistry supported by a world-class faculty, advanced research facilities, and a dynamic community for collaboration.
Academic Excellence and Leadership
To ensure the highest standard in academic oversight, the program involves key University of Bridgeport leadership, including: Elena Cahill, JD, VP of Innovation, Strategy, and Advancement.
Dr. Michael Ciolfi, Dean of the College of Health and Sciences; and
Dr. James Lehman, Director of Health Sciences Postgraduate Education.
The combined expertise of these individuals along with Raghav Goyal Co CEO of TulsiHub ensures the program maintains rigorous academic standards while addressing current industry requirements.
Program Eligibility
The program welcomes medical students, practicing physicians, nurses, chiropractors, and other healthcare professionals seeking specialized and CE certified regenerative medicine expertise. Eligibility encompasses MD, DO, DC, ND, DPM, PA, APRN degree holders, as well as RN, LPN, NP, CRNA, CNS, and CNM professionals.
Visit http://www.tulsihub.com/ to learn more about the courses and our partnership with the University of Bridgeport and Goodwin University.
For media inquiries, please contact:
Email: [email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide. Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages. Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio. America Leans on Hikma represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the Company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients. "We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Dr. Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines." Dr. Bill Larkins, President, Hikma Injectables added, "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines by volume with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients." "As a pharmacist and Chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today," said Rep. Buddy Carter. "Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans' access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete," Rep. Carey said. Hikma remains steadfast in its mission to provide affordable and accessible health care solutions. With this continued investment, Hikma reaffirms its commitment to ensuring a reliable supply of essential medications for all Americans. Contacts : Hikma Pharmaceuticals PLC Investors Susan Ringdal EVP, Strategic Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050 Media Steven Weiss US Communications +1 732 788 8279 About Hikma(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch) Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: View original content to download multimedia: SOURCE Hikma Pharmaceuticals USA Inc.
Yahoo
4 hours ago
- Yahoo
Finland optimistic of building icebreakers for US
Finland is optimistic that it will be able to get around long-standing regulatory barriers to build icebreakers for the US as part of
Yahoo
4 hours ago
- Yahoo
Japan's Tokyo Gas eyes US LNG supply deal
Japan's gas distributor, Tokyo Gas, is currently in discussions with several US liquefied natural gas (LNG) suppliers to finalise a long-term purchase agreement, reported Bloomberg. This strategic move is in response to Japan's increasing reliance on LNG as a critical energy source. The company is engaging with at least four suppliers along the US Gulf Coast, with names such as Energy Transfer and Commonwealth being mentioned by sources familiar with the negotiations. The details of the talks remain confidential as the involved parties have either declined to comment or have not responded to inquiries. This initiative is part of Japan's broader preparation for an anticipated surge in power demand, driven by the growth of data centres and semiconductor manufacturing. The Japanese Government views LNG as an essential component of the nation's energy security and is seeking to secure supplies that could extend beyond 2050. US-sourced LNG is particularly appealing due to its contractual flexibility, which allows Japanese buyers to redirect shipments based on fluctuating domestic needs or more favourable global prices. In addition to securing LNG supplies, Tokyo Gas is also bolstering its presence in the US gas market. The company acquired shale drilling company Rockcliff Energy in late 2023 and has reorganised its US portfolio, including purchasing assets from Chevron in east Texas and divesting its Eagle Ford stake to Shizuoka Gas. In February, Tokyo Gas acquired a 20% stake in FGEN LNG, the owner and operator of an offshore floating LNG terminal in Batangas City in the Philippines. "Japan's Tokyo Gas eyes US LNG supply deal" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
